HODUZA
Live / Allowed — Published for opposition (as of 22 Sept 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 21 Jul 2022 filing date already counts against anyone who files later.
Record
- Serial number
- 97514019
- Mark type
- Word mark
- Filed
- 21 Jul 2022
- Published for opposition
- 22 Sept 2026
- Attorney of record
- Makiko Coffland
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for use in the prevention and the treatment of cancer, rare autoimmune diseases and disorders, autoimmune diseases and disorders, liver diseases, biliary diseases, namely bile ducts and gallbladder, metabolic diseases, namely diabetes, hypoglycemia, gout, arthritis, muscular dystrophy and anemia, inflammatory diseases namely, inflammatory bowel diseases, enteric diseases and inflammatory connective tissue diseases, urological diseases, disorders and diseases of the reproductive system namely, sexual reproduction and fertility, puberty diseases or disorders, namely, precocious puberty, gynecological disorders namely, menstrual irregularities and menopause-related diseases and symptoms, namely, anemia, fertility, acromegalia and tumors, hormonal disorders; pharmaceutical preparations and substances for the prevention and treatment of diseases and disorders of the endocrine system, namely, glucagonoma, growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management, inflammatory connective tissue diseases, blood diseases, gastrointestinal diseases and disorders, hemophilia, gastrointestinal bleeding disorders, neurological diseases, namely, epilepsy, multiple sclerosis, headache, brain tumors, Parkinson's disease, Huntington's disease, Alzheimer's disease, dementia; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders, bone disorders, skeletal disorders, neuromuscular disorders, cervical dystonia, cerebral palsy, spasticity, blepharospasm, migraine, bladder pain syndrome; pharmaceutical preparations and substances for the prevention and treatment of pain, glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin namely, acne, rosacea, dermatitis, psoriasis, vitiligo, hives, alopecia areata, Lupus; pharmaceutical preparations containing botulinum toxin, botulinum toxin-haemagglutinin complex, botulinum toxin fragments and other botulinum toxin derivatives for skin care and the treatment of neurological disorders; pharmaceutical preparations containing botulinum toxin with specified component of the toxin haemagglutinin complex for skin care and the treatment of neurological disorders
Owner
- Clementia Pharmaceuticals Inc., Montreal, Quebec, CA
- Clementia Pharmaceuticals Inc., Montreal, Quebec, CA
Prosecution history
- 22 Sept 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 22 Sept 2026 — PUBLISHED FOR OPPOSITION
- 16 Sept 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 02 Sept 2026 — CASE RETURNED TO EXAMINATION
- 02 Sept 2026 — NOTICE OF ALLOWANCE CANCELLED
- 01 Sept 2026 — PETITION TO DIRECTOR GRANTED
- 31 Aug 2026 — ASSIGNED TO PETITION STAFF
- 22 Jul 2026 — TEAS PETITION TO DIRECTOR RECEIVED
- 09 Jul 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Jul 2026 — SOU EXTENSION 5 GRANTED
- 24 Feb 2026 — SOU EXTENSION 5 FILED
- 09 Jul 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 24 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 23 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Aug 2025 — SOU EXTENSION 4 GRANTED